Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10381161" target="_blank" >RIV/00216208:11140/18:10381161 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/18:10381161

Result on the web

<a href="https://doi.org/10.1111/all.13433" target="_blank" >https://doi.org/10.1111/all.13433</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.13433" target="_blank" >10.1111/all.13433</a>

Result language

angličtina

Original language name

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial

Original language description

Background: Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks. Methods: In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints. Results: The mean reduction in CSMS in the LPP vs placebo group was MINUS SIGN 15.5% (P =.041) during the peak period and MINUS SIGN 17.9% (P =.029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P &lt;.001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P =.005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed LESS-THAN OR EQUAL TO30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (&lt;1%) experienced a serious ESR that resolved with rescue medication. Conclusion: Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated. (C) 2018 The Authors. Allergy Published by John Wiley &amp; Sons Ltd.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30225 - Allergy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Allergy

ISSN

0105-4538

e-ISSN

—

Volume of the periodical

73

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

1842-1850

UT code for WoS article

000443222400009

EID of the result in the Scopus database

2-s2.0-85052753982